aspartic acid has been researched along with Diabetic Ketoacidosis in 6 studies
Aspartic Acid: One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.
aspartic acid : An alpha-amino acid that consists of succinic acid bearing a single alpha-amino substituent
L-aspartic acid : The L-enantiomer of aspartic acid.
Diabetic Ketoacidosis: A life-threatening complication of diabetes mellitus, primarily of TYPE 1 DIABETES MELLITUS with severe INSULIN deficiency and extreme HYPERGLYCEMIA. It is characterized by KETOSIS; DEHYDRATION; and depressed consciousness leading to COMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Bumetanide treatment increased ATP/Pi and PCr/Pi and ameliorated the declines in these values with insulin/saline treatment." | 5.36 | Cerebral metabolic alterations in rats with diabetic ketoacidosis: effects of treatment with insulin and intravenous fluids and effects of bumetanide. ( Anderson, SE; Glaser, N; O'Donnell, ME; Tancredi, DJ; Yuen, N, 2010) |
| "In 25 children, 6-14 years of age, with type 1 diabetes across 3 sites, we acquired T1WI and axial 2D MRSI along with phantom studies to calibrate scanner effects." | 1.91 | Exploratory Multisite MR Spectroscopic Imaging Shows White Matter Neuroaxonal Loss Associated with Complications of Type 1 Diabetes in Children. ( Alonso, GT; Anderson, AW; Cai, LY; Ghetti, S; Glaser, N; Gwal, K; Jaser, SS; Jones, RS; Jordan, LC; Juvera, J; Kang, H; Landman, BA; Lee, CA; LeStourgeon, LM; Mahon, A; Ozturk, A; Patel, NJ; Pruthi, S; Rewers, A; Rewers, MJ; Taki, I; Tanase, C, 2023) |
| "DKA at type 1 diabetes diagnosis results in morphologic and functional brain changes." | 1.40 | Neurological consequences of diabetic ketoacidosis at initial presentation of type 1 diabetes in a prospective cohort study of children. ( Cameron, FJ; Finney, K; Inder, TE; Jennings, J; Koves, I; Mackay, M; Nadebaum, C; Neil, JJ; Northam, EA; Scratch, SE; Wellard, RM, 2014) |
| "Bumetanide treatment increased ATP/Pi and PCr/Pi and ameliorated the declines in these values with insulin/saline treatment." | 1.36 | Cerebral metabolic alterations in rats with diabetic ketoacidosis: effects of treatment with insulin and intravenous fluids and effects of bumetanide. ( Anderson, SE; Glaser, N; O'Donnell, ME; Tancredi, DJ; Yuen, N, 2010) |
| "Subclinical cerebral edema occurs in many, if not most, children with diabetic ketoacidosis (DKA) and may be an indicator of subtle brain injury." | 1.34 | Cerebral proton magnetic resonance spectroscopy in children with diabetic ketoacidosis. ( Barnes, PD; Buonocore, MH; DiCarlo, J; Glaser, NS; Kuppermann, N; Marcin, JP; McCarthy, T; Neely, EK; Wootton-Gorges, SL, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, LY | 1 |
| Tanase, C | 1 |
| Anderson, AW | 1 |
| Patel, NJ | 1 |
| Lee, CA | 1 |
| Jones, RS | 1 |
| LeStourgeon, LM | 1 |
| Mahon, A | 1 |
| Taki, I | 1 |
| Juvera, J | 1 |
| Pruthi, S | 1 |
| Gwal, K | 1 |
| Ozturk, A | 1 |
| Kang, H | 1 |
| Rewers, A | 1 |
| Rewers, MJ | 1 |
| Alonso, GT | 1 |
| Glaser, N | 3 |
| Ghetti, S | 1 |
| Jaser, SS | 1 |
| Landman, BA | 1 |
| Jordan, LC | 1 |
| Cameron, FJ | 1 |
| Scratch, SE | 1 |
| Nadebaum, C | 1 |
| Northam, EA | 1 |
| Koves, I | 1 |
| Jennings, J | 1 |
| Finney, K | 1 |
| Neil, JJ | 1 |
| Wellard, RM | 1 |
| Mackay, M | 1 |
| Inder, TE | 1 |
| Wootton-Gorges, SL | 2 |
| Buonocore, MH | 2 |
| Caltagirone, RA | 1 |
| Kuppermann, N | 2 |
| Glaser, NS | 2 |
| Yuen, N | 2 |
| Anderson, SE | 1 |
| Tancredi, DJ | 1 |
| O'Donnell, ME | 1 |
| Ngo, C | 1 |
| Anderson, S | 1 |
| Trifu, A | 1 |
| O'Donnell, M | 1 |
| Marcin, JP | 1 |
| Barnes, PD | 1 |
| Neely, EK | 1 |
| DiCarlo, J | 1 |
| McCarthy, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Hyperglycemia on Microvascular Perfusion in Healthy Adults[NCT03520569] | Early Phase 1 | 15 participants (Actual) | Interventional | 2019-02-04 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The augmentation index (AIx) measured at the radial artery is a measure of systemic arterial stiffness, and is defined as the ratio of augmentation (Δ P) to central pulse pressure and expressed as percent. AIx = (ΔP/PP) x 100, where P = pressure and PP = Pulse Pressure. Higher percentages indicate increased arterial stiffness. (NCT03520569)
Timeframe: baseline and after 2 hour insulin clamp
| Intervention | percentage (Mean) |
|---|---|
| Octreotide- Euglycemia | -4.15 |
| Octreotide - Euglycemia- Insulin Clamp | -2.23 |
| Octreotide- Hyperglycemia | -4.80 |
| Octreotide- Hyperglycemia - Insulin Clamp | -8.45 |
Flow mediated dilation measures the change in brachial diameter in response to 5 minutes of ischemia using B-mode ultrasound. It provides an index of nitric oxide generation by the endothelium . (NCT03520569)
Timeframe: baseline and after 2 hour insulin clamp
| Intervention | % change (Mean) |
|---|---|
| Octreotide- Euglycemia | 11.8 |
| Octreotide - Euglycemia- Insulin Clamp | 11.8 |
| Octreotide- Hyperglycemia | 8.9 |
| Octreotide- Hyperglycemia - Insulin Clamp | 8.95 |
The time required for a blood pressure wave to travel from the carotid to the femoral artery was measured in meter/sec. This is a measurement of central artery stiffness. Higher numbers indicate stiffer vessels (NCT03520569)
Timeframe: baseline and after 2 hour insulin clamp
| Intervention | m/sec (Mean) |
|---|---|
| Octreotide- Euglycemia | 5.21 |
| Octreotide - Euglycemia- Insulin Clamp | 5.06 |
| Octreotide- Hyperglycemia | 4.79 |
| Octreotide- Hyperglycemia - Insulin Clamp | 5.07 |
6 other studies available for aspartic acid and Diabetic Ketoacidosis
| Article | Year |
|---|---|
Exploratory Multisite MR Spectroscopic Imaging Shows White Matter Neuroaxonal Loss Associated with Complications of Type 1 Diabetes in Children.
Topics: Aspartic Acid; Brain; Child; Choline; Creatine; Diabetes Mellitus, Type 1; Diabetic Ketoacidosis; Gl | 2023 |
Neurological consequences of diabetic ketoacidosis at initial presentation of type 1 diabetes in a prospective cohort study of children.
Topics: Adolescent; Aspartic Acid; Brain; Child; Cognition Disorders; Diabetes Mellitus, Type 1; Diabetic Ke | 2014 |
Progressive decrease in N-acetylaspartate/Creatine ratio in a teenager with type 1 diabetes and repeated episodes of ketoacidosis without clinically apparent cerebral edema: Evidence for permanent brain injury.
Topics: Adolescent; Aspartic Acid; Basal Ganglia; Blood Glucose; Brain; Brain Damage, Chronic; Brain Edema; | 2010 |
Cerebral metabolic alterations in rats with diabetic ketoacidosis: effects of treatment with insulin and intravenous fluids and effects of bumetanide.
Topics: Animals; Aspartic Acid; Brain; Brain Edema; Bumetanide; Cerebrovascular Circulation; Creatinine; Dia | 2010 |
Effects of hyperglycemia and effects of ketosis on cerebral perfusion, cerebral water distribution, and cerebral metabolism.
Topics: Adenosine Triphosphate; Animals; Aspartic Acid; Brain Edema; Cerebrum; Diabetes Mellitus, Experiment | 2012 |
Cerebral proton magnetic resonance spectroscopy in children with diabetic ketoacidosis.
Topics: Adolescent; Aspartic Acid; Brain; Brain Edema; Child; Choline; Consciousness Disorders; Creatine; Di | 2007 |